(2R,4aS,6aR,6aS,14aS,14bR)-10-acetyloxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid | 158835-46-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (2R,4aS,6aR,6aS,14aS,14bR)-10-acetyloxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
• CAS: 158835-46-2
• 化学式: C₃₁H₄₀O₅
• 分子量: 492.656
• InChiKey: DNLGFGXSBOIDNV-ZRCCSVPJSA-N

物化性质

• 沸点：
  666.1±55.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  36
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  80.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  雷公藤红素 、 乙酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以15.8%的产率得到(2R,4aS,6aR,6aS,14aS,14bR)-10-acetyloxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
  参考文献：
  名称：

  [EN] ANALOGS OF CELASTROL
  [FR] ANALOGUES DE CÉLASTROL

  摘要：

  本文描述了用于治疗或预防肥胖以及使用这些方法的组合物和方法。

  公开号：

  WO2017070615A1

文献信息

• Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof
  申请人：University of Florida Research Foundation, Inc.

  公开号：EP2374451A2

  公开（公告）日：2011-10-12

  The invention features compositions and methods that are useful for treating or preventing a protein conformation disease in a subject by correcting misfolded proteins in vivo. In addition, the invention provides compositions and methods that are useful for expressing a recombinant protein in a biochemically functional conformation.

  本发明的特点是通过纠正体内错误折叠的蛋白质来治疗或预防受试者的蛋白质构象疾病的组合物和方法。此外，本发明还提供了以生化功能构象表达重组蛋白的组合物和方法。
• Analogs of celastrol
  申请人：ERX Pharmaceuticals, Inc.

  公开号：US10662218B2

  公开（公告）日：2020-05-26

  Described herein, inter alia, are compositions and methods for treating or preventing obesity and using the same.

  本文特别描述了治疗或预防肥胖症的组合物和方法，以及使用这些组合物和方法的方法。
• Synthesis and preliminary evaluation of neuroprotection of celastrol analogues in PC12 cells
  作者：Hongli Sun、Lipeng Xu、Pei Yu、Jie Jiang、Gaoxiao Zhang、Yuqiang Wang

  DOI：10.1016/j.bmcl.2010.05.066

  日期：2010.7

  A series of celastrol analogues were synthesized, and their neuroprotective effect against t-BHP-induced cytotoxicity was investigated in neuronal PC12 cells. Their effects on Hsp70 protein expression were quantified by Western blot analysis. The study found that compound CL12 is more effective than the parent celastrol against t-BHP-induced cytotoxicity. CL12 up-regulates Hsp70 protein expression dose-dependently. These results suggest that CL12 is a potential candidate for the intervention of neurodegenerative diseases. (c) 2010 Elsevier Ltd. All rights reserved.
• Small Compounds That Correct Protein Misfolding and Uses Thereof
  申请人：Kaushal Shalesh

  公开号：US20100004156A1

  公开（公告）日：2010-01-07

  The invention features compositions and methods that are useful for treating or preventing a protein conformation disease in a subject by correcting misfolded proteins in vivo. In addition, the invention provides compositions and methods that are useful for expressing a recombinant protein in a biochemically functional conformation.
• COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF
  申请人：The Children's Medical Center Corporation

  公开号：US20150274634A1

  公开（公告）日：2015-10-01

  Pentacyclic triterpene compounds are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the compounds, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The compounds can also be co-administered with leptin or a leptin analog.